Plaintiff's Xarelto victory is short-lived as judge overturns $28M verdict against Bayer and J&a

Fierce Pharma ----------- The first verdict to go against Bayer and Johnson & Johnson over Xarelto's bleeding risks didn't stand up to court scrutiny. A U.S. judge overturned the $28 million award on grounds it was an unreasonable result. In the case of Lynn Hartman, Judge Michael Erdos in Philadelphia this week entered a judgment notwithstanding the verdict, which is a finding that a no reasonable jury could have reached the same conclusion. Hartman brought the case in Pennsylvania, arguing her Xarelto use—prescribed to prevent strokes associated with atrial fibrillation—caused severe gastrointestinal bleeding, according to Reuters. The case was the first to go to trial in state courts over Xarelto bleeding risks, a J&J spokesperson previously said. To learn more click on the picture below to read the article.